Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program – Yahoo Finance

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program.
BURNABY, British Columbia, January 17, 2023–(BUSINESS WIRE)–Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005450/en/
NIHB clients of all ages with type 1 diabetes are now eligible for coverage of the Dexcom G6 CGM System. (Photo: Business Wire)
“Indigenous, First Nations and Inuit communities are disproportionately impacted by diabetes beyond childhood and adolescence, making this announcement a key step forward to ensuring better glucose control, improved health outcomes and reduced risk of developing diabetes-related complications,” said Dr. Jeff Winterstein, an Edmonton-based internal medicine specialist who works with many NIHB patients who live with diabetes. “Furthermore, CGM can help to bridge the distance between remote communities and care providers. The Dexcom CLARITY software allows me to remotely see a patient’s glucose data and trends over time so I can make the appropriate adjustments and treatment decisions.”
Dexcom rtCGM use is proven to improve glycemic control^1,2 and can reduce the risk of costly long-term diabetes-related complications.³ As part of the NIHB coverage program, clients aged 2 to 19 on intensive insulin therapy AND clients of all ages with type 1 diabetes can now obtain their Dexcom G6 rtCGM supplies directly from their local pharmacy.
“CGM positively impacts the health^1,2 of both pediatric and adult patients and expanded access is an important step forward in creating a more equitable healthcare system across the country,” says Laura Endres, Senior Vice President of Dexcom. “We applaud the NIHB for offering more people the chance to take control of their health and live better with diabetes.”
Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device^* or receiver, giving patients real-time glucose data without the need to scan or prick their finger routinely.^† The system has customizable and predictive alerts and alarms to help avoid potentially dangerous low and high blood sugar events and a function that allows patients to share their glucose data in real time with up to 10 followers.
Dexcom G6 also offers industry-leading connectivity through integrations with leading insulin delivery systems and digital health apps.
For more information on Dexcom G6, please visit https://www.dexcom.com/en-CA/en-ca-dexcom-g6-cgm-system
To search the online NIHB Drug Benefit List for Dexcom G6 coverage details, go to https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407
About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
^† If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
^* For a list of compatible devices, please visit dexcom.com/compatibility
References
¹ Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
² Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
³ Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor Versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. Poster presentation presented at: 2020 Canadian Association for Population Therapeutics; October 27, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005450/en/
Contacts
Alena Atkinson, 705.206.9991
Veritas Communications
atkinson@veritasinc.com
Related Quotes
Sector ETF report for RTM
David Pastrnak (Boston Bruins) with a Goal vs. Philadelphia Flyers, 01/16/2023
The tech sector had a difficult year in 2022, as soaring inflation followed by rapidly rising interest rates brought the sector back down from the meteoric valuations it saw in 2021. The outlook for this year is still quite uncertain, with liquidity tightening and the impact of all of the Fed's rate hikes still largely unknown. The Invesco QQQ Trust (NASDAQ: QQQ) is a popular tech ETF because it owns many headline-grabbing tech stocks like Apple, Microsoft, Amazon, Alphabet, and Meta Platforms, just to name some of its largest holdings.
Arthur J. Gallagher (AJG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
An experimental vaccine from Moderna significantly reduced the risk of a viral respiratory disease among older adults in a large clinical trial, the latest promising sign in drugmakers’ efforts to fight the deadly RSV virus. Citing the results, the Cambridge, Mass., company said Tuesday it would apply in the coming months for U.S. regulatory approval to sell its vaccine against RSV, which stands for respiratory syncytial virus. Moderna’s RSV vaccine was 83.7% effective against lower-respiratory diseases caused by RSV in the study, the company said.
Federal health agencies are investigating whether there is a link between BioNTech and Pfizer’s bivalent COVID-19 booster and stroke in seniors.
A common virus that can cause severe illness in older adults and young children, RSV cases were particularly widespread in the U.S. this fall.
Last month, one of its anti-psychotic drugs received approval from the Food and Drug Administration for another indication.
Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults.
Edesa Biotech Inc (NASDAQ: EDSA) announced preliminary topline results from a Phase 2b study evaluating multiple concentrations of the company's drug candidate, EB01, as monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis. EB01 is a non-steroidal anti-inflamamatory compound that inhibits secretory phospholipase 2. Edesa reported that 1.0% EB01 cream demonstrated statistically significant improvement over the placebo. For the primary endpoint, patients with 1.0% EB01-treated le
Temple Health said the insurer "doesn't seem to understand how health care is provided in Philadelphia."
Novocure will win a 10% of its targeted lung cancer market, an analyst predicted Tuesday as he examined NVCR stock's double-digit drop.
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Is Pfizer stock a buy or a sell after getting a downgrade on its falling Covid-tied sales? Is PFE stock a buy or a sell right now?
"What's driving the category are demographics, aging of the population, as well as [an] increase in diabetes and diabetic eye disease," Regeneron CEO Len Schleifer said during the 41st annual J.P. Morgan Healthcare Conference in San Francisco.
“It baffles the mind that you would have anyone, let alone a child, waiting for 10 hours to receive treatment for a fractured leg,” the family’s lawyer said.
A new subvariant of omicron, XBB.1.5, has been called by world health leaders the most transmissible version of the coronavirus yet.
Eating just one serving of freshwater fish each year could have the same effect as drinking water heavily polluted with “forever chemicals” for an entire month, a new study finds. The equivalent monthlong amount of water would be contaminated at levels 2,400 times greater than what’s recommended by the Environmental Protection Agency’s (EPA) drinking water…
The FDA has approved Abbott Laboratories (NYSE: ABT) latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio, offering less invasive treatment options. Aortic stenosis occurs when the aortic valve's opening narrows, restricting blood flow to the body. Lef
Carbon Health CEO Eren Bali speaks with Yahoo Finance’s Anjalee Khemlani about the health technology platform, doubling down on primary care, health care quality, and different business models in the industry.

source